CHAPEL HILL, N.C., Feb. 17, 2011 /PRNewswire/ — Recent
biopharmaceutical product launches have produced both noteworthy
failures and successes. Faced with a continually evolving launch
landscape, organizations are rethinking the factors that play the
biggest role in the current launch environment. In a new
wide-ranging research project that explores the pivotal success
factors and failure points facing new product launches, Best
Practices, LLC established a critical core set of factors that can
make or break a market entry.
The report, Success Factors and
Failure Points in Biopharmaceutical Product Launches: An Updated
Road Map for Strong Market Entry, presents a framework for
launch success: the ability to differentiate, a defined
target patient population, investment in launch activities,
engagement of thought leaders, education of key stakeholders,
demonstration of value, utilization of new technologies and
avoidance of launch pitfalls.
In addition to delivering qualitative and quantitative insights
on each aspect of this launch framework, the 148-page report
presents launch leaders’ perspectives on the current and future
risk levels for an array of pitfall factors that can affect a
launch. The pitfall areas touch on patient and payer pitfalls as
well as physician and regulatory stumbling blocks.
To download a complimentary study excerpt, go to: http://www3.best-in-class.com/rr1042.htm.
Best Practices, LLC used both field surveys and interviews to
complete this study. In all, 44 managers and executives at 38
leading biopharma companies participated in the survey.
In-depth interviews were conducted with leaders who have
decades of experience with pharma launches. The research report
includes 11 of the Top 20 biopharma firms and three of the six
interviews were with Top 10 pharma companies.
Topics covered
‘/>”/>
